GNVC pancreatic cancer drug INCREASED SURVIVAL BY 8 MONTHS. For pancreatic that is a revolutionary result, $5 target. Compare Tarceva, which added 15 days to overall survival over 6 months.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.